Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment

被引:0
作者
Huang, Ching-Wen [1 ,2 ,3 ]
Yeh, Yung-Sung [1 ,4 ,5 ]
Ma, Cheng-Jen [1 ,4 ]
Tsai, Hsiang-Lin [1 ,3 ,6 ]
Chen, Chao-Wen [5 ,7 ,8 ]
Huang, Ming-Yii [9 ,10 ]
Lu, Chien-Yu [11 ,12 ]
Wu, Jeng-Yih [11 ,12 ]
Wang, Jaw Yuan [1 ,2 ,3 ,4 ,7 ,13 ]
机构
[1] Kaohsiung Med Univ Hosp, Div Gastroenterol & Gen Surg, Dept Surg, Kaohsiung, Taiwan
[2] Kaohsiung Med Univ Hosp, Div Colorectal Surg, Dept Surg, Kaohsiung, Taiwan
[3] Kaohsiung Med Univ Hosp, Coll Med, Grad Inst Med, Kaohsiung, Taiwan
[4] Kaohsiung Med Univ Hosp, Coll Med, Grad Inst Clin Med, Kaohsiung, Taiwan
[5] Kaohsiung Med Univ Hosp, Dept Surg, Div Trauma, Kaohsiung, Taiwan
[6] Kaohsiung Med Univ Hosp, Dept Surg, Div Gen Surg Med, Kaohsiung, Taiwan
[7] Kaohsiung Med Univ Hosp, Coll Med, Fac Med, Dept Surg, Kaohsiung, Taiwan
[8] Kaohsiung Med Univ Hosp, Dept Emergency Med, Kaohsiung, Taiwan
[9] Kaohsiung Med Univ Hosp, Dept Radiat Oncol, Kaohsiung, Taiwan
[10] Kaohsiung Med Univ Hosp, Coll Med, Dept Radiat Oncol, Fac Med, Kaohsiung, Taiwan
[11] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan
[12] Kaohsiung Med Univ, Coll Med, Fac Med, Dept Internal Med, Kaohsiung, Taiwan
[13] Kaohsiung Med Univ, Ctr Biomarkers & Biotech Drugs, Kaohsiung, Taiwan
关键词
Bevacizumab; Dose escalation; Irinotecan; Hyperbilirubinemia; Metastatic colorectal cancer; UGT1A1; SEVERE LIVER DYSFUNCTION; SOLID TUMOR PATIENTS; HEPATIC-DYSFUNCTION; 5-FLUOROURACIL LEUCOVORIN; ORGAN DYSFUNCTION; OXALIPLATIN; IRINOTECAN; CPT-11;
D O I
10.1159/000447118
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastatic colorectal cancer (mCRC) combined with hyperbilirubinemia is typically considered a contraindication to irinotecan-based therapy, a proven first-line treatment of mCRC. Herein, we present 6 consecutive patients with mCRC combined with hyperbilirubinemia who underwent UGT1A1 genotyping before receiving FOLFIRI plus bevacizumab. Dose escalation of irinotecan was performed according to the results of UGT1A1 genotyping in all patients. Improvement in the serum total bilirubin level to a normal range was noted in all 6 patients. Disease control was 100%. The median progression-free survival was 7.5 months and the median overall survival was 8.5 months. FOLFIRI plus bevacizumab as a first-line chemotherapy may achieve effective disease control and be safe in patients with mCRC and hyperbilirubinemia based on UGT1A1 genotyping. More prospective clinical studies are necessary to evaluate the clinical benefits and safety of this treatment approach. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:80 / 84
页数:5
相关论文
共 20 条
[1]   New Developments in the Second-Line Treatment of Metastatic Colorectal Cancer: Potential Place in Therapy [J].
Arnold, Dirk ;
Stein, Alexander .
DRUGS, 2013, 73 (09) :883-891
[2]   Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer [J].
Cartwright, Thomas H. .
CLINICAL COLORECTAL CANCER, 2012, 11 (03) :155-166
[3]   Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: A preliminary report of the national cancer institute organ dysfunction working group [J].
Doroshow, JH ;
Synold, TW ;
Gandara, D ;
Mani, S ;
Remick, SC ;
Mulkerin, D ;
Hamilton, A ;
Sharma, S ;
Ramanathan, RK ;
Lenz, HJ ;
Graham, M ;
Longmate, J ;
Takimoto, CH ;
Ivy, P .
SEMINARS IN ONCOLOGY, 2003, 30 (04) :14-19
[4]   5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction [J].
Fakih, MG .
ONCOLOGY, 2004, 67 (3-4) :222-224
[5]   Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction [J].
Fleming, GF ;
Schilsky, RL ;
Schumm, LP ;
Meyerson, A ;
Hong, AM ;
Vogelzang, NJ ;
Ratain, MJ .
ANNALS OF ONCOLOGY, 2003, 14 (07) :1142-1147
[6]   Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel [J].
Grenader, Tal ;
Goldberg, Anthony ;
Gabizon, Alberto .
ANTI-CANCER DRUGS, 2009, 20 (09) :845-847
[7]   Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases [J].
Gruenberger, Birgit ;
Scheithauer, Werner ;
Punzengruber, Robert ;
Zielinski, Christoph ;
Tamandl, Dietmar ;
Gruenberger, Thomas .
BMC CANCER, 2008, 8 (1)
[8]   Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting [J].
Lu, Chien-Yu ;
Huang, Ching-Wen ;
Hu, Huang-Ming ;
Tsai, Hsiang-Lin ;
Huang, Chun-Ming ;
Yu, Fang-Jung ;
Huang, Ming-Yii ;
Chang, Se-Fen ;
Huang, Meng-Lin ;
Wang, Jaw-Yuan .
TRANSLATIONAL RESEARCH, 2014, 164 (02) :169-176
[9]   Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction [J].
Ong, SYK ;
Clarke, SJ ;
Bishop, J ;
Dodds, HM ;
Rivory, LP .
ANTI-CANCER DRUGS, 2001, 12 (07) :619-625
[10]   Biologic therapies in the metastatic colorectal cancer treatment continuum - Applying current evidence to clinical practice [J].
Peeters, Marc ;
Price, Timothy .
CANCER TREATMENT REVIEWS, 2012, 38 (05) :397-406